Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency

Autor: L'Houcine Ouafik, Crescent C Gbeto, Catherine Roche, Bruno Lacarelle, Sylvie Quaranta, Thierry Allegre, Sophie Nahon, Roxane Mari, Raphaelle Fanciullino, Caroline Solas, Joseph Ciccolini

Publikováno v: Pharmacogenomics
Pharmacogenomics, Future Medicine, 2019, 20 (13), pp.931-938. ⟨10.2217/pgs-2019-0028⟩
Pharmacogenomics, 2019, 20 (13), pp.931-938. ⟨10.2217/pgs-2019-0028⟩

Dihydropryimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with severe or lethal toxicities with oral capecitabine. Usually, patients with history of 5-FU-based therapy with no signs for life-threatening toxicities are

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a80ad7d0eee8b7de3adb5b0b21c92db8
https://pubmed.ncbi.nlm.nih.gov/31486738